Neurocrine Biosciences announced data analysis from two phase 3 trials evaluating opicapone added to levodopa for Parkinson’s disease was presented at an oral session at…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.